NEW YORK
- Powerful Medical partners with Roche to bring real-time, AI-powered ECG interpretation from PMcardio to the cobas® pulse point-of-care system, enhancing chest pain diagnostics at the bedside.
- This solution, combined with Roche’s Elecsys® high-sensitivity cardiac Troponin T test, enables healthcare professionals to confidently rule in or rule out heart attacks (acute myocardial infarction).
- Cardiovascular disease causes one-third of deaths worldwide, with chest pain being the second most common reason for emergency department visits.
Powerful Medical today announced a collaboration with Roche to integrate PMcardio, a leading AI-powered electrocardiogram (ECG) interpretation tool, into the cobas® pulse ecosystem, a cutting-edge point-of-care platform. This partnership is designed to improve the diagnostic process for patients presenting with chest pain, a leading cause of emergency department visits.
Chest pain accounts for millions of emergency visits annually. Rapid ECG interpretation is critical for diagnosing ST-elevation myocardial infarction (STEMI), the most severe type of heart attack, and for making timely decisions to ensure patients reach the catheterization lab within 90 minutes—helping to prevent permanent damage and reduce mortality. When STEMI is not indicated on the ECG, high-sensitivity cardiac troponin testing serves as the gold standard to confirm or rule out myocardial infarction safely.
By combining PMcardio’s advanced AI ECG interpretation with the cobas® pulse system’s smart biomarker testing, healthcare providers now have access to a unified platform at the patient’s bedside. This integration facilitates faster and more accurate clinical decisions, increasing diagnostic confidence and streamlining the identification of acute myocardial infarction, including STEMI and its equivalents, in real time.
Dr. Robert Herman, PhD, Chief Medical Officer at Powerful Medical, said, “Our goal is to deliver the quickest and most precise method for ruling in or ruling out acute MI. By combining AI-driven ECG analysis with high-sensitivity troponin T testing, we aim to close diagnostic gaps, improve patient outcomes, and reduce healthcare costs.”
This collaboration reinforces PMcardio’s role as a scalable and clinically trusted AI platform, working with Roche to create the most comprehensive, digitally enhanced, and time-sensitive diagnostic pathway for chest pain patients right at the point of care.
About Powerful Medical and PMcardio
PMcardio is a diagnostic and care coordination platform created by Powerful Medical, a company specializing in AI-driven cardiovascular diagnostics. Clinically validated to detect 49 cardiac conditions from an ECG, PMcardio can identify acute heart attacks up to three hours earlier and with twice the sensitivity compared to current standard methods. This capability enables prompt and accurate triage in emergency settings, helping to reduce treatment delays and door-to-balloon times. PMcardio supports optimized care for patients experiencing chest pain. The platform is already class IIb CE-marked under the EU MDR in Europe and is awaiting FDA approval, enhancing acute cardiac care by enabling faster, more confident clinical decision-making.
